NDC 66869-564

SEGLENTIS

Celecoxib And Tramadol Hydrochloride

SEGLENTIS is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Kowa Pharmaceuticals America, Inc.. The primary component is Celecoxib; Tramadol Hydrochloride.

Product ID66869-564_cf2c8436-a9f4-473c-e053-2a95a90a1123
NDC66869-564
Product TypeHuman Prescription Drug
Proprietary NameSEGLENTIS
Generic NameCelecoxib And Tramadol Hydrochloride
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2022-01-01
Marketing CategoryNDA /
Application NumberNDA213426
Labeler NameKowa Pharmaceuticals America, Inc.
Substance NameCELECOXIB; TRAMADOL HYDROCHLORIDE
Active Ingredient Strength56 mg/1; mg/1
Pharm ClassesCyclooxygenase Inhibitors [MoA],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC],Full Opioid Agonists [MoA],Opioid Agonist [EPC]
DEA ScheduleCIV
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 66869-564-90

1 BOTTLE, PLASTIC in 1 CARTON (66869-564-90) > 90 TABLET in 1 BOTTLE, PLASTIC
Marketing Start Date2022-01-01
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [SEGLENTIS]

Mark Image

Registration | Serial
Company
Trademark
Application Date
SEGLENTIS
SEGLENTIS
87827471 not registered Live/Pending
ESTEVE PHARMACEUTICALS, S.A.
2018-03-09

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.